Aldehyde dehydrogenase 2 ameliorates doxorubicin-induced myocardial dysfunction through detoxification of 4-HNE and suppression of autophagy

Journal of Molecular and Cellular Cardiology

Volumn 71, Issue , 2014, Pages 92-104

  Sun, Aijun ^a   Cheng, Yong ^a,c   Zhang, Yingmei ^b   Zhang, Qian ^a,d   Wang, Shijun ^a   Tian, Shan ^e   Zou, Yunzeng ^a   Hu, Kai ^a   Ren, Jun ^a,b   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

4 HNE; ALDH2; Autophagy; Dilated cardiomyopathy; Doxorubicin

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE DEHYDROGENASE ISOENZYME 2; AUTOPHAGY PROTEIN 5; BECLIN 1; CELL MARKER; DOXORUBICIN; ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ALDA 1; PROTEIN KINASE B; PROTEIN LC3 II; RAPAMYCIN; UNCLASSIFIED DRUG; 4-HYDROXY-2-NONENAL; ALDEHYDE; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 2, MOUSE; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; BIOACCUMULATION; CELL VIABILITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE DELETION; GENETIC TRANSFECTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR SIGNALING; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIOMYOPATHY; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; DRUG INACTIVATION; ENZYMOLOGY; GENETICS; HEART; HEART CONTRACTION; HEART MUSCLE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION;

MUS;

ALDEHYDE DEHYDROGENASE; ALDEHYDES; ANIMALS; AUTOPHAGY; CARDIOMYOPATHIES; DOWN-REGULATION; DOXORUBICIN; FEMALE; HEART; HUMANS; INACTIVATION, METABOLIC; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84899922979     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.01.002     Document Type: Article

References (56)

1. Stewart M.J., Malek K., Crabb D.W. Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. J Investig Med 1996, 44:42-46.
2. Zhang Y., Ren J. ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications. Pharmacol Ther 2011, 132:86-95.
3. Chen C.H., Budas G.R., Churchill E.N., Disatnik M.H., Hurley T.D., Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008, 321:1493-1495.
4. Doser T.A., Turdi S., Thomas D.P., Epstein P.N., Li S.Y., Ren J. Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation 2009, 119:1941-1949.
5. Wang J., Wang H., Hao P., Xue L., Wei S., Zhang Y., et al. Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol Med 2011, 17:172-179.
6. Ma H., Yu L., Byra E.A., Hu N., Kitagawa K., Nakayama K.I., et al. Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression: role of protein phosphatases. J Mol Cell Cardiol 2010, 49:322-329.
7. Zhang Y., Babcock S.A., Hu N., Maris J.R., Wang H., Ren J. Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3beta and mitochondrial function. BMC Med 2012, 10:40.
8. Sun A., Ren J. ALDH2, a novel protector against stroke?. Cell Res 2013, 23:874-875.
9. Guo J.M., Liu A.J., Zang P., Dong W.Z., Ying L., Wang W., et al. ALDH2 protects against stroke by clearing 4-HNE. Cell Res 2013, 23:915-930.
10. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990, 4:3076-3086.
11. Mukhopadhyay P., Batkai S., Rajesh M., Czifra N., Harvey-White J., Hasko G., et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007, 50:528-536.
12. Pacher P., Liaudet L., Bai P., Virag L., Mabley J.G., Hasko G., et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002, 300:862-867.
13. Nemchenko A., Chiong M., Turer A., Lavandero S., Hill J.A. Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol 2011, 51:584-593.
14. Xie M., Morales C.R., Lavandero S., Hill J.A. Tuning flux: autophagy as a target of heart disease therapy. Curr Opin Cardiol 2011, 26:216-222.
15. Yitzhaki S., Huang C., Liu W., Lee Y., Gustafsson A.B., Mentzer R.M., et al. Autophagy is required for preconditioning by the adenosine A1 receptor-selective agonist CCPA. Basic Res Cardiol 2009, 104:157-167.
16. De Meyer G.R., De Keulenaer G.W., Martinet W. Role of autophagy in heart failure associated with aging. Heart Fail Rev 2010, 15:423-430.
17. Mathew R., Kongara S., Beaudoin B., Karp C.M., Bray K., Degenhardt K., et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007, 21:1367-1381.
18. Zhang Y.S., He L., Liu B., Li N.S., Luo X.J., Hu C.P., et al. A novel pathway of NADPH oxidase/vascular peroxidase 1 in mediating oxidative injury following ischemia-reperfusion. Basic Res Cardiol 2012, 107:266.
19. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007, 117:1782-1793.
20. Ceylan-Isik A.F., Dong M., Zhang Y., Dong F., Turdi S., Nair S., et al. Cardiomyocyte-specific deletion of endothelin receptor A rescues aging-associated cardiac hypertrophy and contractile dysfunction: role of autophagy. Basic Res Cardiol 2013, 108:335.
21. Ito H., Daido S., Kanzawa T., Kondo S., Kondo Y. Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 2005, 26:1401-1410.
22. Karantza-Wadsworth V., Patel S., Kravchuk O., Chen G., Mathew R., Jin S., et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007, 21:1621-1635.
23. Kostin S., Pool L., Elsasser A., Hein S., Drexler H.C., Arnon E., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003, 92:715-724.
24. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lullmann-Rauch R., et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000, 406:902-906.
25. Wang X., Robbins J. Proteasomal and lysosomal protein degradation and heart disease. J Mol Cell Cardiol 2013.
26. Kassiotis C., Ballal K., Wellnitz K., Vela D., Gong M., Salazar R., et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 2009, 120:S191-S197.
27. Ma H., Guo R., Yu L., Zhang Y., Ren J. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur Heart J 2011, 32:1025-1038.
28. Bian Y., Chen Y.G., Xu F., Xue L., Ji W.Q., Zhang Y. The polymorphism in aldehyde dehydrogenase-2 gene is associated with elevated plasma levels of high-sensitivity C-reactive protein in the early phase of myocardial infarction. Tohoku J Exp Med 2010, 221:107-112.
29. Pavan M., Ruiz V.F., Silva F.A., Sobreira T.J., Cravo R.M., Vasconcelos M., et al. ALDH1A2 (RALDH2) genetic variation in human congenital heart disease. BMC Med Genet 2009, 10:113.
30. Xu F., Chen Y.G., Xue L., Li R.J., Zhang H., Bian Y., et al. Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndrome. J Cell Mol Med 2011, 15:1955-1962.
31. Ge W., Guo R., Ren J. AMP-dependent kinase and autophagic flux are involved in aldehyde dehydrogenase-2-induced protection against cardiac toxicity of ethanol. Free Radic Biol Med 2011, 51:1736-1748.
32. Zhang B., Zhang Y., La Cour K.H., Richmond K.L., Wang X.M., Ren J. Mitochondrial aldehyde dehydrogenase obliterates endoplasmic reticulum stress-induced cardiac contractile dysfunction via correction of autophagy. Biochim Biophys Acta 1832, 2013:574-584.
33. Yalcin E., Oruc E., Cavusoglu K., Yapar K. Protective role of grape seed extract against doxorubicin-induced cardiotoxicity and genotoxicity in albino mice. J Med Food 2010, 13:917-925.
34. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., et al. p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
35. Zou Y., Zhu W., Sakamoto M., Qin Y., Akazawa H., Toko H., et al. Heat shock transcription factor 1 protects cardiomyocytes from ischemia/reperfusion injury. Circulation 2003, 108:3024-3030.
36. Krusche C.A., Holthofer B., Hofe V., van de Sandt A.M., Eshkind L., Bockamp E., et al. Desmoglein 2 mutant mice develop cardiac fibrosis and dilation. Basic Res Cardiol 2011, 106:617-633.
37. Wold L.E., Aberle N.S., Ren J. Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect Prev 2005, 29:294-299.
38. Jay S.M., Murthy A.C., Hawkins J.F., Wortzel J.R., Steinhauser M.L., Alvarez L.M., et al. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation 2013, 128:152-161.
39. Kobayashi S., Volden P., Timm D., Mao K., Xu X., Liang Q. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 2010, 285:793-804.
40. Yao Y., Xu X., Zhang G., Zhang Y., Qian W., Rui T. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway. Basic Res Cardiol 2012, 107:267.
41. Aberle N.S., Picklo M.J., Amarnath V., Ren J. Inhibition of cardiac myocyte contraction by 4-hydroxy-trans-2-nonenal. Cardiovasc Toxicol 2004, 4:21-28.
42. Zhu W., Shou W., Payne R.M., Caldwell R., Field L.J. A mouse model for juvenile doxorubicin-induced cardiac dysfunction. Pediatr Res 2008, 64:488-494.
43. Diwan A., Dorn G.W. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) 2007, 22:56-64.
44. Shimomura H., Terasaki F., Hayashi T., Kitaura Y., Isomura T., Suma H. Autophagic degeneration as a possible mechanism of myocardial cell death in dilated cardiomyopathy. Jpn Circ J 2001, 65:965-968.
45. Keizer H.G., Pinedo H.M., Schuurhuis G.J., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990, 47:219-231.
46. Petersen D.R., Doorn J.A. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004, 37:937-945.
47. Yan L.J., Sohal R.S. Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Proc Natl Acad Sci U S A 1998, 95:12896-12901.
48. Hill B.G., Haberzettl P., Ahmed Y., Srivastava S., Bhatnagar A. Unsaturated lipid peroxidation-derived aldehydes activate autophagy in vascular smooth-muscle cells. Biochem J 2008, 410:525-534.
49. Tjalkens R.B., Cook L.W., Petersen D.R. Formation and export of the glutathione conjugate of 4-hydroxy-2, 3-E-nonenal (4-HNE) in hepatoma cells. Arch Biochem Biophys 1999, 361:113-119.
50. Yan F., Wang M., Chen H., Su J., Wang X., Wang F., et al. Gambogenic acid mediated apoptosis through the mitochondrial oxidative stress and inactivation of Akt signaling pathway in human nasopharyngeal carcinoma CNE-1 cells. Eur J Pharmacol 2011, 652:23-32.
51. Zhang Y., Ren J. Thapsigargin triggers cardiac contractile dysfunction via NADPH oxidase-mediated mitochondrial dysfunction: role of Akt dephosphorylation. Free Radic Biol Med 2011, 51:2172-2184.
52. Lee J.H., Won Y.S., Park K.H., Lee M.K., Tachibana H., Yamada K., et al. Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis 2012, 17:1275-1286.
53. Ginion A., Auquier J., Benton C.R., Mouton C., Vanoverschelde J.L., Hue L., et al. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am J Physiol Heart Circ Physiol 2011, 301:H469-H477.
54. Morrison A., Yan X., Tong C., Li J. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am J Physiol Heart Circ Physiol 2011, 301:H895-H902.
55. Zhang Y., Ren J. Autophagy in ALDH2-elicited cardioprotection against ischemic heart disease: slayer or savior?. Autophagy 2010, 6:1212-1213.
56. Turdi S., Xu P., Li Q., Shen Y., Kerram P., Ren J. Amidization of doxorubicin alleviates doxorubicin-induced contractile dysfunction and reduced survival in murine cardiomyocytes. Toxicol Lett 2008, 178:197-201.